References
- 1McLeod BC, Piehl MR, Sassetti RJ. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 1990; 59:185–9.
- 2Hong F, Ruiz R,Price H,et al. Safety profile of WinRho anti-D. Semin Hematol 1998;35(Suppl):9–13.
- 3Package insert: Rho (D) Immune Globulin Intravenous (Human)/WinRho SDF™ Cangene Corporation, Winnipeg, Canada. Distributed by Nabi, Boca Raton, FL.
- 4Standards for Blood Banks and Transfusion Services. 16th ed. Bethesda, MD: American Association of Blood Banks, 1994.
- 5Standards for Blood Banks and Transfusion Services. 18th ed.Bethesda,MD: American Association of BloodBanks, 1996.
- 6Hartwell EA. Use of Rh immune globulin/ASCP practice parameter. Am J Clin Pathol 1998;110:281–92.
- 7Urbaniak SJ. Consensus conference on anti-D prophylaxis, April 7 & 8,1997: final consensus statement, Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynecologists. Transfusion 1998;38:97–9.
- 8Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford, England: Blackwell Science, 1997:175.
- 9McGinniss MH, Bronson WR, Freireich E, Kliman A. Formation of red cell antibodies in response to platelet transfusions.Transfusion 1963;3:426.
- 10Goldfinger D, McGinniss MH. Rh-incompatible platelet transfusions—risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971;284:942–4.
- 11Lichtiger B, Surgeon J, Rhorer S. Rh-incompatible platelet transfusion therapy in cancer patients.Vox Sang 1983;45:139–43.
- 12Lichtiger B, Hester JP.Transfusion of Rh-incompatible blood components to cancer patients. Haematologia 1986;19:81–8.